

From the Chief Medical Officer, Professor Dame Sally C Davies FRS FMedSci

18 December 2015

To: All general practitioners On-line pharmacy services Richmond House 79 Whitehall London SW1A 2NS

T: +44 (0)20 7210 5151-4 F: +44 (0)20 7210 5407 E: sally.davies@dh.gsi.gov.uk

W: www.gov.uk

Dear colleague

## **GONORRHOEA AND ANTIMICROBIAL RESISTANCE**

As you will be aware, antimicrobial resistance (AMR) is a growing clinical and public health issue of the greatest importance. It has long been recognised that gonorrhoea is at risk of becoming an untreatable disease due to the continuing emergence of AMR. In one area of the North of England a "resistance alert" related to an on-going outbreak of high-level azithromycin resistant gonorrhoea has been issued<sup>1</sup>. We are therefore writing to underline the importance of effective antimicrobial stewardship for **all** prescribing for this infection.

Since 2011, the approach in the UK and in other countries has been to recommend the use of **dual therapy of injectable ceftriaxone and oral azithromycin**. Gonorrhoea has rapidly acquired resistance to new antibiotics, leaving few alternatives to the current recommendations. It is therefore extremely important that suboptimal treatment does not occur and, if services lack facilities to provide injectable drugs, patients are referred to a Genitourinary Medicine (GUM) clinic or sexual health service for management.

We therefore ask that you review your prescribing practice and treatment protocols to ensure that they meet the national guidelines produced by the British Association for Sexual health and HIV<sup>2</sup>. For health professionals involved in remote and/or on-line prescribing there is guidance from the General Medical Council<sup>3</sup> and the General Pharmaceutical Council. <sup>4</sup>

We attach great importance to this issue. We need to ensure that those diagnosed with gonorrhoea receive optimal and appropriate treatment in order to ensure effective care for that individual, protect public health and reduce the risk of AMR.

PROFESSOR DAME SALLY C DAVIES

DR KEITH RIDGE CBE, CHIEF PHARMACEUTICAL OFFICER

 $<sup>^{1}\,\</sup>underline{\text{https://www.gov.uk/government/publications/health-protection-report-volume-9-2015/hpr-volume-9-issue-41-news-20-november}$ 

http://www.bashh.org/documents/3920.pdf

<sup>&</sup>lt;sup>3</sup> Good practice in prescribing and managing medicines and devices: (<a href="http://www.gmcuk.org/static/documents/content/Prescribingguidance.pdf">http://www.gmcuk.org/static/documents/content/Prescribingguidance.pdf</a>

<sup>&</sup>lt;sup>4</sup>http://www.pharmacyregulation.org/sites/default/files/guidance for registered pharmacies on distance and internet services .pdf